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The identification of Three cancer 
stem cell subpopulations within 
Moderately Differentiated lip 
squamous cell carcinoma
Rachna Ram1, Helen D. Brasch1, Jonathan C. Dunne1, Paul F. Davis1, Swee T. Tan1,2*† and 
Tinte Itinteang1†
1 Gillies McIndoe Research Institute, Wellington, New Zealand, 2 Wellington Regional Plastic, Maxillofacial and Burns Unit, 
Hutt Hospital, Wellington, New Zealand
aim: To identify and characterize cancer stem cells (CSCs) in moderately differentiated 
lip squamous cell carcinoma (MDLSCC).
Method: MDLSCC samples underwent 3,3-diaminobenzidine (DAB) immunohis-
tochemical (IHC) staining for squamous cell carcinoma marker EMA, CSC marker 
CD44 and embryonic stem cell markers NANOG, octamer-binding transcription factor 
4 (OCT4), spalt-like transcription factor 4 (SALL4), sex-determining region Y-box 2 
(SOX2), and phosphorylated signal transducer and activator of transcription 3 (pSTAT3). 
Immunofluorescent IHC staining was performed on two MDLSCC samples. Western 
blotting (WB) was used to confirm the expression of the aforementioned proteins and 
their transcription activation was investigated using NanoString and RT-qPCR.
results: IHC staining demonstrated the presence of (1) an EMA+/CD44+/SALL4+/
NANOG+/pSTAT3+/SOX2+/OCT4− CSC subpopulation within the tumor nests (TNs); 
(2) a CD44+/SALL4+/NANOG+/pSTAT3+/SOX2+/OCT4− CSC subpopulation; and (3) 
a CD44+/SALL4+/NANOG+/pSTAT3+/SOX2+/OCT4+ CSC subpopulation within the 
stroma, between the TNs. NanoString and RT-qPCR confirmed the presence of mRNA 
for CD44, SALL4, STAT3, SOX2, and OCT4, and WB confirmed the presence of NANOG, 
pSTAT3, SOX2, and OCT4.
conclusion: This study demonstrates three putative CSC subpopulations within 
MDLSCC.
Keywords: lip, oral cavity, squamous cell, carcinoma, cancer stem cell, cancer
Abbreviations: DAB, 3,3-diaminobenzidine; CSC, cancer stem cell; ESC, embryonic stem cell; H&E, hematoxylin and eosin; IF, 
immunofluorescent; IHC, immunohistochemical; MDLSCC, moderately differentiated lip squamous cell carcinoma; OCSCC, 
oral cavity squamous cell carcinoma; SCC, squamous cell carcinoma; TN, tumor nest; WB, Western blotting.
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inTrODUcTiOn
Lip cancer constitutes a subsite of oral cavity cancer with more 
than 80% being squamous cell carcinoma (SCC) (1). There 
is a higher incidence of lip SCC in males in North America 
(12.7/100,000 per annum), Europe (12.0/100,000 per annum), 
and Oceania (13.5/100,000 per annum) (2) and the incidence is 
rising among females (2).
The etiological factors for oral cavity SCC (OCSCC) includ-
ing lip SCC include allelic imbalance involving tumor suppressor 
genes (3), oncogenes (3), and carcinogen metabolizing enzymes 
(4), and the risk factors include tobacco use (5), immune deficiency 
(6), UV exposure (6), and human papilloma virus infection (7, 8). 
An overall 5-year survival rate of 88–97% has been reported (1, 
9), and this is reduced to 78% in the presence of nodal metastasis 
and local recurrence (9–11). While surgery and radiotherapy are 
equally effective for the treatment of early lip SCC, combined 
treatment is required for advanced lesions (12).
There is growing evidence supporting the hierarchical model 
of carcinogenesis, which proposes that the development, growth, 
and spread of cancer are driven by a small population of cancer 
stem cells (CSCs) (13, 14). Various methods used for identifica-
tion of CSCs in OCSCC include Hoechst dye exclusion, sphere 
forming assays, aldehyde dehydrogenase activity, and CSC 
marker identification (such as CD44, CD133, E-cadherin, kerat-
ins, and integrins) (14–16). More recent studies have utilized the 
embryonic stem cell (ESC) markers, sex-determining region Y 
(SRY)-box 2 (SOX2) (17), octamer-binding transcription factor 4 
(OCT4) (17, 18), phosphorylated signal transducer and activator 
of transcription 3 (pSTAT3) (19), spalt-like transcription factor 4 
(SALL4) (20), and Homeobox protein NANOG (18) to identify 
CSCs within OCSCC (21, 22).
CD44 is a transmembrane glycoprotein, a receptor for the 
glycosaminoglycan hyaluronan (23), and a CSC marker associ-
ated with cell proliferation, migration, and differentiation (24). 
SOX2 is a member of the SOX (SRY-related HMG Box) gene (25), 
encoding transcription factors with a single HMG DNA-binding 
domain and its suppression is considered vital to maintain stem 
cell pluripotency (17, 26). OCT4 is a POU domain transcription 
factor that works synergistically with SOX2 to regulate ESC 
pluripotency (27). SALL4 is an ESC marker that plays a role in 
multiple cancer types by regulating proliferation, apoptosis, 
chemoresistance, and maintenance of CSCs (23, 28), as well as 
modulating expression of pSTAT3, which is required for tumor 
formation, growth, and suppression of apoptosis (29). NANOG 
is a transcription factor that plays an essential role in maintaining 
stemness of ESC and controls cell proliferation, migration, and 
invasion (27, 30).
We have recently identified and characterized CSC subpopu-
lations within oral tongue (21) and buccal mucosal (22) SCC. 
Although there are a number of reports on the presence and role 
of CSCs in OCSCC (21), there is paucity of data on the presence 
of CSC in lip SCC. This study aimed to identify and characterize 
the CSC subpopulations within moderately differentiated lip 
SCC (MDLSCC) using the SCC marker EMA, the CSC marker 
CD44, and the ESC markers SOX2, OCT4, pSTAT3, SALL4, and 
NANOG, at both the transcriptional and translational levels.
MaTerials anD MeThODs
Tissue samples
Previously untreated primary MDLSCC samples from one female 
and nine male patients, aged 46–94  years (mean, 64.4  years), 
were sourced from the Gillies McIndoe Research Institute and 
used for this study, which was approved by the Central Health 
and Disabilities Ethics Committee (ref. no. 12/CEN/74).
histochemical and immunohistochemical 
(ihc) staining
Hematoxylin and eosin (H&E) staining was performed on 
4-μm thick formalin-fixed paraffin-embedded blocks of 10 
MDLSCC samples that were subsequently analyzed by an ana-
tomical pathologist (Helen D. Brasch) to confirm the presence 
of SCC and the histological grading. 3,3-Diaminobenzidine 
(DAB) IHC staining for NANOG (1:100; cat# ab80892, 
Abcam, Cambridge, MA, USA), SOX2 (1:200; cat# PA1-094, 
Thermo Fisher Scientific, Waltham, MA, USA), SALL4 (1:30; 
cat# CM385M-16, Cell Marque, Rocklin, CA, USA), pSTAT3 
(1:100; cat# 9145, Cell Signaling Technology, Danvers, MA, 
USA), OCT4 (1:1,000; cat# ab109183, Abcam), CD44 (1:1,500; 
cat# MRQ-13, Cell Marque), and epithelial membrane antigen 
(EMA, ready-to-use; cat# PA0035, Leica) diluted with Bond™ 
primary antibody diluent (Leica AR9352) was performed on the 
tissue sections using the Leica Bond Rx auto-stainer (Leica) as 
previously described (21, 31).
Immunofluorescent (IF) IHC staining was performed 
on two representative MDLSCC samples from the original 
cohort used for DAB IHC staining to investigate protein co-
expression. Vectafluor Excel anti-rabbit 594 (ready-to-use; 
cat# VEDK-1594, Vector Laboratories, Burlingame, CA, 
USA) and Alexa Fluor anti-mouse 488 (1:500; cat# A21202, 
Thermo Fisher Scientific) were used to detect combinations 
that included NANOG, SOX2, or pSTAT3 and VectaFluor 
Excel anti-mouse (ready-to-use; cat# VEDK2488, Vector 
Laboratories) and Alexa Fluor anti-rabbit 594 (1:500; cat# 
A21207, Thermo Fisher Scientific) were used to detect com-
binations that included OCT4 or SALL4. All IF IHC-stained 
slides were mounted in Vectashield HardSet Antifade mount-
ing medium with 4′,6-diamidino-2-phenylindole (cat#H-1500, 
Vector Laboratories).
Positive human control tissues used for the primary antibod-
ies were skin for EMA, tonsil for CD44, pSTAT3 and SOX2, and 
seminoma for NANOG, SALL4, and OCT4. Negative antibody 
control was performed on one MDLSCC sample per antibody 
staining run.
image analysis
DAB IHC-stained slides were viewed using an Olympus BX53 
light microscope (Tokyo, Japan) and the images were captured 
with the CellSens 2.0 software (Olympus). IF IHC-stained slides 
were viewed and the images were captured using an Olympus 
FV1200 biological confocal laser-scanning microscope and 
processed with the CellSens Dimension 1.11 software using 2D 
deconvolution algorithm (Olympus).
FigUre 1 | representative DaB immunohistochemical-stained sections of moderately differentiated lip squamous cell carcinoma demonstrating 
nuclear membrane staining of cD44 [(a), brown] on cells within the stroma and cell membrane staining on cells within the tumor nests (Tns). Nuclear 
staining of NANOG [(B), red] was seen in cells within the TNs and the stroma. Patchy areas of weak staining for phosphorylated signal transducer and activator of 
transcription 3 [(c), brown] was detected on cells within the TNs. Focal moderate expression of spalt-like transcription factor 4 [(D), brown] on cells within the TNs 
and weak staining on cells within the stroma. Widespread and strong staining of sex-determining region Y-box 2 [(e), brown] was seen on cells within the TNs and 
the stroma. Staining for octamer-binding transcription factor 4 [(F), red] was limited to cells within the stroma. Original magnification: 200×.
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nanostring gene expression analysis
Total RNA was isolated and quantified as previously described (31) 
from six snap-frozen MDLSCC samples from the original cohort 
of 10 patients used for DAB IHC staining. They were subjected 
to the NanoString nCounter gene expression assay (NanoString 
Technologies, Seattle, WA, USA) by New Zealand Genomics 
(Dunedin, New Zealand). Briefly, total RNA was extracted using 
the MagJET RNA kit (Thermo Fisher Scientific) with the pro-
tocol adapted for tissue and run on a KingFisher Duo machine 
(Thermo Fisher Scientific). RNA samples were then quantitated 
on a Qubit® 2.0 fluorometer (Thermo Fisher Scientific) and 
were subject to RNA integrity analysis via the 2100 Bioanalyzer 
Instrument (Agilent Technologies). Probes for the genes encod-
ing CD44 (NM_001001392.1), NANOG (NM_024865.2), OCT4 
(NM_002701.4), STAT3 (NM_139276.2), and the housekeeping 
genes glucuronidase beta (GUSB) (NM_000181.1), clathrin heavy 
chain (CLTC) (NM_4859.2), and hypoxanthine phosphoribosyl-
transferase 1 (NM_000194.1) were designed and manufactured 
by NanoString Technologies. Raw data were analyzed using 
nSolver™ software (NanoString Technologies) using standard 
settings and normalized against the housekeeping gene.
rT-qPcr
Total RNA was isolated from six snap-frozen MDLSCC samples 
from the original cohort of 10 patients used for DAB IHC stain-
ing using the RNeasy mini Kit (Qiagen) with a DNase digest 
and the QIAcube system (Qiagen). Total RNA quantity and 
quality were assessed using NanoDrop 2000 (Thermo Fisher 
Scientific). Reverse transcription reactions were performed using 
the iScript Reverse Transcription Supermix for RT-qPCR (Bio-
Rad, Hercules, CA, USA). The expression of stem cell markers 
was detected using gene-specific TaqMan primers-probe sets 
(SOX2: Hs01053049_s1; SALL4: Hs00360675_m1) with the 
Rotor-Gene Multiplex RT-PCR Kit (Qiagen). All measurements 
were performed in triplicate and relative mRNA expression was 
determined by the ΔΔCt method. GAPDH was used as the 
endogenous control and probe-specific gBlocks gene sequences 
(IDT technologies) were used as calibrators. All samples with 
a threshold cycle ≥35.0 were considered negative. Graphs were 
generated with Microsoft Excel and results are shown as relative 
expression.
Western Blotting (WB)
Six snap-frozen MDLSCC samples from the original cohort 
of 10 patients included in DAB IHC staining underwent WB 
as previously described (32), using primary antibodies for 
NANOG (1:1,000; cat# ab47102, Abcam), OCT4 (1:2,000; cat# 
ab109183, Abcam), pSTAT3 (1:1,000; cat# 9145, Cell Signaling 
Technology), SOX2 (1:1,000; cat# PA1-094, Thermo Fisher 
Scientific), and β-actin (1:1,000; ab8226, Abcam). Two primary 
antibodies were used for SALL4 (1:1,000, cat# ab57577 and 
1:1,000, cat# ab157172, both from Abcam). Secondary antibod-
ies used were goat anti-rabbit horseradish peroxidase (HRP) 
conjugate (1:10,000; cat# A16110, Thermo Fisher Scientific) 
or Alexa Fluor® 647 rabbit anti-mouse (1:2,000; cat# A21239, 
Thermo Fisher Scientific) as appropriate. HRP conjugated 
secondary antibody detection was achieved using Clarity™ 
Western ECL substrate (Bio-Rad). Membranes were imaged 
using a ChemiDoc MP imaging system (Bio-Rad).
resUlTs
histochemical and ihc staining
Hematoxylin and eosin staining confirmed the diagnosis and his-
tological grading of MDLSCC in all 10 samples. Staining patterns 
FigUre 2 | representative immunofluorescent immunohistochemical-stained sections of moderately differentiated lip squamous cell carcinoma 
demonstrating the expression of sex-determining region Y-box 2 (sOX2) [(a), red] by the eMa+ [(a), green] cells within the Tns and the stroma. SOX2 
[(B,c), red] was expressed by cells within both the TNs and the stroma that expressed CD44 [(B), green] and spalt-like transcription factor 4 [(c), green]. Expression 
of NANOG [(D), red] and phosphorylated signal transducer and activator of transcription 3 [(e), red] was seen in cells within the TNs and the stroma that expressed 
CD44 [(D,e), green]. Octamer-binding transcription factor 4 [(F), green] was expressed in a proportion of cells within the stroma that expressed SOX2 [(F), red]. Cell 
nuclei were counterstained with 4′,6-diamidino-2-phenylindole [(a–F), blue]. Scale bars: 20 μm.
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for the CSC markers in all 10 samples are shown in Table S1 in 
Supplementary Material.
DAB IHC staining demonstrated that some cells within the 
tumor nests (TNs) stained positively with the SCC marker EMA 
(data not shown), as expected. There was also membranous 
staining of the CSC marker CD44 (Figure 1A, brown) that was 
localized to cells within the TNs and the stroma. Staining of 
NANOG (Figure 1B, red), pSTAT3 (Figure 1C, brown), SALL4 
(Figure 1D, brown), and SOX2 (Figure 1E, brown) was localized 
to cells within the TNs and the stroma. Immunoreactivity for 
OCT4 (Figure 1F, red) was primarily cytoplasmic and focal in 
cells within the stroma.
Expected staining patterns for CD44, NANOG, pSTAT3, 
SALL4, SOX2, and OCT4 (Figure S1 in Supplementary 
FigUre 3 | log10 relative expression of cancer stem cell-related 
mrna transcripts in six moderately differentiated lip squamous cell 
carcinoma samples analyzed by nanostring (a) and rT-qPcr (B). 
Expression is depicted relative to the clathrin heavy chain housekeeping gene 
(a) and the GAPDH housekeeping gene (B). CD44 and STAT3 were detected 
in all six samples, NANOG was undetectable in all six samples, while 
octamer-binding transcription factor 4 was detected in four out of six 
samples (a). Sex-determining region Y-box 2 and spalt-like transcription 
factor 4 were detected in all six samples (B).
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Material) were demonstrated in the respective positive con-
trols. An appropriate negative control by the omission of the 
primary antibody in MDLSCC samples provided a control 
for the secondary antibody (Figure S2 in Supplementary 
Material).
Immunofluorescent IHC staining performed on two rep-
resentative MDLSCC samples from the original cohort of 10 
patients used for DAB IHC staining demonstrated expression 
of the SCC marker EMA (Figure  2A, green) by cells within 
the TNs, while SOX2 (Figure  2A, red) was localized to cells 
within both the TNs and the stroma. Dual staining of SOX2 
(Figures 2B,C, red) with CD44 (Figure 2B, green) and SALL4 
(Figure  2C, green) showed that SOX2 was localized to cells 
within the TNs and the stroma that also expressed CD44 and 
SALL4. Co-staining of NANOG (Figure 2D, red) and pSTAT3 
(Figure  2E, red) with CD44 (Figures  2D,E, green) demon-
strated that the CD44+ cells within the TNs and the stroma also 
expressed NANOG and pSTAT3. Interestingly, the expression 
of OCT4 (Figure 2F, green) was confined only to a proportion 
of SOX2+ (Figure 2F, red) cells within the stroma. Images of the 
individual stains are presented in Figure S3 in Supplementary 
Material.
nanostring gene expression analysis
NanoString transcriptional profiling of the six MDLSCC samples 
from the original cohort of 10 patients used for DAB IHC staining 
normalized against the housekeeping genes GUSB, CLTC, and 
HPRT1 confirmed the relative abundance of mRNA for CD44 
and STAT3 in all the six samples. OCT4 was detected in four 
out of the six samples, while NANOG was undetectable in all six 
samples (Figure 3A).
rT-qPcr
RT-qPCR analysis of six snap-frozen MDLSCC samples from the 
original cohort of 10 patients used for DAB IHC staining dem-
onstrated abundance of mRNA transcripts for SOX2 and SALL4 
in all six samples (Figure 3B).
Western Blotting
Western blot analysis of six snap-frozen MDLSCC samples from 
the original cohort of 10 patients included in DAB IHC staining 
showed that NANOG was detected in all six samples (Figure 4A). 
OCT4 was detected in two of the six samples (Figure 4B), pSTAT3 
was detected in five of the six samples (Figure 4C), and SOX2 was 
detected in all six samples (Figure 4D). A band corresponding to 
the expected size of SALL4 was undetectable by WB in any of the 
six samples (data not shown).
DiscUssiOn
This study adds to the growing body of evidence for the pres-
ence of CSCs in OCSCC. Our study demonstrates the presence 
of three distinct CSC subpopulations within MDLSCC (1): a 
CD44+/SALL4+/NANOG+/pSTAT3+/SOX2+/OCT4− subpopula-
tion within the TNs (2); a CD44+/SALL4+/NANOG+/pSTAT3+/
SOX2+/OCT4−, and (3) a CD44+/SALL4+/NANOG+/pSTAT3+/
SOX2+/OCT4+ CSC subpopulation within the stroma of 
MDLSCC. It is exciting to speculate that the interactions between 
the CSCs within the TNs and the adjacent stromal environment 
may promote migration of CSCs away from the TNs, into the 
stroma, giving rise to the CSC subpopulations within the stroma, 
potentially via an epithelial–mesenchymal transition process 
(33–35). Alternatively, the primitive subpopulations within the 
stroma may represent normal “resident” stem cells, although this 
is a topic of further investigation.
The novel identification of more than one subpopulation 
of CSCs within MDLSCC parallels our recent findings in oral 
tongue (21) and buccal mucosa (22) SCC. Determination of 
which CSC subpopulation within the stroma possess the capac-
ity for epithelial–mesenchymal transition (36) is a subject of 
further work, and we believe that a new paradigm opens up in the 
investigation of the biology of this tumor. The putative interplay 
between the stromal and TN CSC subpopulations raises the pos-
sibility of the CSC subpopulation within the TN giving rise to the 
CSC subpopulations within the stroma, which possess the ability 
to migrate away to establish local and distant TNs, although this 
is the subject of further investigation.
NANOG and SOX2 were expressed on cells within the TNs 
and the stroma. Overexpression of SOX2 in tumors has been cor-
related with increased tumor thickness and invasion, metastasis 
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in esophageal cancer, drug resistance, and decreased survival in 
tumors such as breast cancer and lung adenocarcinoma (26, 37). 
Similarly, overexpression of NANOG is associated with unfavora-
ble tumor features and poor survival of OCSCC patients (38).
Interestingly, OCT4 is expressed exclusively by the CSC sub-
population within the stroma. It is intriguing that the expression 
of OCT4 demonstrated by IHC staining in the stroma of all 10 
MDLSCC samples was supported by NanoString and WB analy-
ses in only two out of six samples. This may be due to sampling 
bias and/or antibody specificity. Investigating the expression 
of OCT4 in head and neck SCC samples of 119 patients, Koo 
et al. (39) demonstrate no staining and weak staining of OCT4 
in 5% and 34% of the samples, respectively. Higher expression 
of OCT4 correlates significantly with poor histologic grade and 
worse overall and disease-specific survival in head and neck 
SCC (39).
Wu et al. (40) examined 156 pancreatic cancer tissue samples 
and found that high nuclear expression of pSTAT3 was associ-
ated with higher tumor grade and shorter median survival, 
compared to those with low expression of pSTAT3. Our IHC 
staining results showing weak expression of pSTAT3 by cells 
in both the TNs and the stroma is interesting and may reflect 
a tumor with relatively better prognosis. The relatively moder-
ate expression of SALL4 as detected by IHC staining may be 
explained by the fact that only MDLSCC was analyzed in this 
study. High SALL4 expression levels have been correlated with 
poor overall survival of patients with aggressive tumors such 
as hepatocellular, endometrial cancer, gastric, and esophageal 
cancer (28).
This report demonstrates three putative subpopulations 
of CSCs within MDLSCC. It adds to the increasing support of 
the hierarchical concept of cancer. Further study may provide 
FigUre 4 | representative western blot analysis performed on six moderately differentiated lip squamous cell carcinoma samples demonstrating 
detection of nanOg across all six samples (a), octamer-binding transcription factor 4 in two samples (B), phosphorylated signal transducer and 
activator of transcription 3 in five samples (c), and sex-determining region Y-box 2 in all six samples (D).
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